American International Group, Inc. Aurinia Pharmaceuticals Inc. Transaction History

American International Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.93 - $9.31 $2,824 - $5,334	-573 Reduced 0.85%	66,738 $334,000
Q4 2023 Feb 13, 2024	SELL	$7.13 - $9.49 $1,939 - $2,581	-272 Reduced 0.4%	67,311 $605,000
Q3 2023 Nov 13, 2023	BUY	$7.77 - $12.27 $18,671 - $29,484	2,403 Added 3.69%	67,583 $525,000
Q2 2023 Aug 04, 2023	BUY	$8.96 - $11.69 $3,915 - $5,108	437 Added 0.67%	65,180 $630,000
Q1 2023 May 12, 2023	BUY	$5.94 - $11.27 $7,650 - $14,515	1,288 Added 2.03%	64,743 $709,000
Q4 2022 Feb 10, 2023	SELL	$4.11 - $8.14 $949 - $1,880	-231 Reduced 0.36%	63,455 $274,000
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $5,994 - $11,151	900 Added 1.43%	63,686 $479,000
Q2 2022 Aug 12, 2022	BUY	$8.95 - $12.8 $561,934 - $803,660	62,786 New	62,786 $631,000

191

56.2M

499K

637K

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.04B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.